Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02828618
Recruitment Status : Active, not recruiting
First Posted : July 11, 2016
Last Update Posted : August 16, 2019
Sponsor:
Information provided by (Responsible Party):
AGO Study Group

Brief Summary:

This study consists of three parts, whereas Part 1 and Part 2 are performed in Germany only, and Part 3 is a multinational trial.

All patients with suspicion of advanced ovarian cancer are detected in the participating study centers in a pre-screening. The study centers will register all patients with suspected ovarian cancer in a screening log. After the patients have given informed consent, they can be enrolled in different parts of the study.

TRUST-Trial: This part compares two strategies in the therapy of advanced ovarian cancer. En detail, this part of the trial will evaluate if one of two strategies of timing surgery within the therapeutic procedures may show any significant advances in terms of overall survival over the other.


Condition or disease Intervention/treatment Phase
Ovarian Cancer Procedure: PDS (Primary Debulkdung Surgery) Procedure: 6 cycles of standard chemotherapy Procedure: Timing of surgery after 3 cycles of standard NACT, IDS Procedure: IDS Drug: 3 cycles of standard chemotherapy Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 797 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Study Start Date : July 2016
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Arm Intervention/treatment
Active Comparator: Arm I PDS and chemotherapy
PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
Procedure: PDS (Primary Debulkdung Surgery)
PDS with maximum effort to achieve the goal of complete gross resection

Procedure: 6 cycles of standard chemotherapy
6 cycles of standard chemotherapy after Primary Debuling Surgery

Experimental: Arm II Timing of surgery after 3 cycles of SOC CTX
3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
Procedure: Timing of surgery after 3 cycles of standard NACT, IDS
Timing of surgery after 3 cycles of standard NACT

Procedure: IDS
IDS with maximum effort to achieve the goal of complete gross resection after NACT

Drug: 3 cycles of standard chemotherapy
3 more cycles (for a total of 6) of standard chemotherapy after IDS




Primary Outcome Measures :
  1. overall survival (OS) [ Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death ]

    To compare the overall survival (OS) after primary debulking surgery (PDS) versus interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) in patients with FIGO (2014) stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma.

    The primary endpoint overall survival time is calculated from the date of randomization until the date of death from any cause or date of last contact (censored observation).



Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death ]
    Progression-free survival time is calculated from the date of randomization until the date of first progressive disease or death, whichever occurs first or date of last contact (censored observation). Progressive disease is defined as clinical or imaging-detected tumor progression or death in cases without prior documented tumor progression.

  2. Progression-free survival 2 (PFS2) [ Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death ]
    PFS2 time is calculated from the date of randomization until the date of second progressive disease or death, whichever occurs first or date of last contact (censored observation).

  3. Time to first subsequent anticancer therapy or death (TFST) [ Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death ]
    Time to first subsequent anticancer therapy is calculated from the date of randomization until the starting date of the first subsequent anticancer therapy or death, whichever occurs first or date of last contact (censored observation). Maintenance treatments following a cytostatic treatment are not considered separate treatment lines.

  4. Time to second subsequent anticancer therapy or death (TSST) [ Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death ]
    Time to second subsequent anticancer therapy is calculated from the date of randomization until the starting date of the second subsequent anticancer therapy or death, whichever occurs first or date of last contact (censored observation). Maintenance treatments following a cytostatic treatment are not considered separate treatment lines.

  5. Quality of life (QoL) [ Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death ]
    Quality of life (QoL) as measured by EORTC QLQ-C30 (Version 3), EORTC QLQ-OV28, EQ-5D-3L

  6. Documentation of surgical complications [ Time Frame: Patients will be followed up for 1 year after surgery or until death ]
    Assessment of safety: documentation of surgical complications 28 days after surgery and 1 year after surgery.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer FIGO stage IIIB-IV (IV only if resectable metastasis)
  • Females aged ≥ 18 years
  • Patients who have given their written informed consent
  • Good performance status (ECOG 0/1)
  • Good ASA score (1/2)
  • Preoperative CA 125/CEA ratio ≥ 25 (if CA-125 is elevated)*
  • If <25 and/or biopsy with non-serous, non-endometroid histology, esophago-gastro-duodenoscopy (EGD) and colonoscopy mandatory to exclude gastrointestinal primary cancer
  • Assessment of an experienced surgeon, that based on all available information, the patient can undergo the procedure and the tumor can potentially be completely resected
  • Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. This ANC cannot have been induced or supported by granulocyte colony stimulating factors.
  • Platelet count ≥ 100 x 109/L.
  • Renal function: Serum-Creatinine ≤ 1.5 x institutional upper limit normal (ULN).
  • Hepatic function:

    • Bilirubin ≤ 1.5 x ULN.
    • SGOT ≤ 3 x ULN
    • Alkaline phosphatase ≤ 2.5 x ULN.
  • Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade 1.

Exclusion Criteria:

  • Non epithelial ovarian malignancies and borderline tumors
  • Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity.
  • Recurrent ovarian cancer
  • Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy
  • Unresectable parenchymal lung metastasis, liver metastasis or bulky lymph-nodes in the mediastinum in CT chest and abdomen/pelvis
  • Clinical relevant dysfunctions of blood clotting (including drug induced)
  • Any significant medical reasons, age or performance status that will not allow to perform the study procedures (estimation of investigator)
  • Pregnancy
  • Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent
  • Any reasons interfering with regular follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02828618


Locations
Show Show 20 study locations
Sponsors and Collaborators
AGO Study Group
Investigators
Layout table for investigator information
Principal Investigator: Sven Mahner, Professor MD AGO Study Group
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AGO Study Group
ClinicalTrials.gov Identifier: NCT02828618    
Other Study ID Numbers: AGO-OVAR OP.7/TRUST
First Posted: July 11, 2016    Key Record Dates
Last Update Posted: August 16, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type